As highlighted in recent reviews [57,58,133], the potential of APN/CD13 as a target for tumor therapy has prompted a series of pre-clinical and clinical studies systematically investigating the effects of the inhibitors/ligands of APN/CD13, alone or in combination. Here, ANPEP is linked to neoplasm.